Neutralizing antibodies against SARS-CoV-2 in Brazilian pregnant women vaccinated with one or two doses of BNT162b2 mRNA vaccine (Pfizer/Wyeth TM ).

Autor:	da Silva MC; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil., da Silva NCH; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil., Ferreira ALCG; Women Health Research Group of Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil., Ferreira FCG; University of Pernambuco, Recife, Brazil., de Melo MIB; Pernambuco College of Health (FPS), Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil., da Silva LMX; Pernambuco College of Health (FPS), Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil., Barbosa CRM; Clinical Hospital, Federal University of Pernambuco, Recife, Brazil., de Magalhães JJF; Central Laboratory of Pernambuco, State Secretary of Health, Recife, Brazil., Diniz GTN; Laboratory of Computational Methods, Aggeu Magalhães Institute, Recife, Brazil., Souza AI; Women Health Research Group of Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil., Lucena-Silva N; Laboratory of Immunogenetics, Department of Immunology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in public health [Front Public Health] 2023 Jan 04; Vol. 10, pp. 1054460. Date of Electronic Publication: 2023 Jan 04 (Print Publication: 2022).
DOI:	10.3389/fpubh.2022.1054460
Abstrakt:	Pregnant women have an increased risk of developing severe coronavirus disease. In Brazil, the number of hospitalizations and adverse outcomes, including death caused by COVID-19, in women during the pregnancy-puerperal cycle was high in the first pandemic year. Doubts regarding vaccines' efficacy and safety for the mother and fetus delayed vaccination. This study evaluated the generation of IgG titers and neutralizing antibodies to the BNT162b2 mRNA vaccine in 209 healthy pregnant women. For this, were used the QuantiVac ELISA (IgG) and SARS-CoV-2 NeutraLISA kits (EUROIMMUN, Lübeck, SH) following the manufacturer's recommendations. One dose vaccine produced anti-SARS-CoV-2 IgG in 85% (81/95), and two produced in 95% (76/80) women. Among unvaccinated women, four of 34 (12%) showed protection. The first dose of the BNT162b2 vaccine protected 69% of the women with neutralizing antibodies (median of %IH = 97). In the second dose, protection occurred in 94% of the pregnant women (median of IH% = 97). This study showed no differences in IgG antibody titers between one- and two-dose of the BNT162b2 mRNA vaccine groups, boosting with the second dose increased the number of women who produced specific IgG and neutralizing antibodies, raising by 114-folds the chance of producing the SARS-CoV-2 neutralizing antibodies compared to the unvaccinated pregnant woman, which may contribute to reduce the chance of severe COVID-19. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Silva, Silva, Ferreira, Ferreira, Melo, Silva, Barbosa, Magalhães, Diniz, Souza and Lucena-Silva.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu